© 2001 by European Society of Cardiology
Copyright © 2000, European Society of Cardiology
Vasoactive intestinal peptide: cardiovascular effects
Department of Medicine, University of South Florida College of Medicine and the James A. Haley Hospital, Tampa, FL, USA
* Corresponding author. Correspondence address. James A. Haley Hospital, 13000 Bruce B. Downs Blvd., 111, Tampa, FL 33612, USA. Tel.: +1-813-978-5873; fax: +1-813-978-5884
Vasoactive intestinal peptide (VIP) is present in the peripheral and the central nervous systems where it functions as a nonadrenergic, noncholinergic neurotransmitter or neuromodulator. Significant concentrations of VIP are present in the gastrointestinal tract, heart, lungs, thyroid, kidney, urinary bladder, genital organs and the brain. On a molar basis, VIP is 50–100 times more potent than acetylcholine as a vasodilator. VIP release in the body is stimulated by high frequency (10–20 Hz) nerve stimulation and by cholinergic agonists, serotonin, dopaminergic agonists, prostaglandins (PGE, PGD), and nerve growth factor. The VIP peptide combines with its receptor and dose-dependently activates adenylyl cyclase. The vasodilatory effect of VIP in different vascular tissues or species also may be due to increases in nitric oxide, cyclic GMP, and other signaling agents. In the heart, VIP immunoreactive nerve fibers are present not only in the epicardial coronary arteries and veins, but also the sinoatrial node, atrium, interatrial septum, atrioventricular node, intracardiac ganglia, and ventricles (right ventricle >> left ventricle). In the coronary arterial walls, VIP may contribute to the regulation of normal coronary vasomotor tone. In research animals and in humans, VIP, administered into the coronary artery or intravenously, increases the epicardial coronary artery cross-sectional area, decreases coronary vascular resistance, and significantly increases coronary artery blood flow. High frequency parasympathetic (vagal) nerve stimulation also releases endogenous VIP in the coronary vessels and heart and significantly increases coronary artery blood flow. In addition, the release of VIP in the heart is increased during coronary artery occlusion and during reperfusion where VIP may promote local blood flow and may have a free-radical scavenging effect. VIP also has a primary positive inotropic effect on cardiac muscle that is enhanced by its ability to facilitate ventricular–vascular coupling by reducing mean arterial pressure by 10–15%. In concentrations of 10–8–10–5 mol, VIP augments developed isometric force and increases atrial and ventricular contractility. The presence of VIP-immunoreactive nerve fibers in and around the sinus and the atrioventricular nodes of mammals strongly suggests that this peptide can affect the heart rate. In this regard, endogenously released or exogenous VIP can significantly increase the heart rate and has a more potent effect on heart rate than does norepinephrine. The presence and significant cardiovascular effects of VIP in the heart suggests that this peptide is important in the regulation of coronary blood flow, cardiac contraction, and heart rate. Current investigations are defining the physiological role of VIP in the regulation of cardiovascular function.
KEYWORDS Contractile function; Coronary circulation; Heart rate (variability); Neurotransmitters; Vasoconstriction/dilation
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. A. Szliter, S. Lighvani, R. P. Barrett, and L. D. Hazlett Vasoactive Intestinal Peptide Balances Pro- and Anti-Inflammatory Cytokines in the Pseudomonas aeruginosa-Infected Cornea and Protects against Corneal Perforation J. Immunol., January 15, 2007; 178(2): 1105 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Schlereth, J. O. Dittmar, B. Seewald, and F. Birklein Peripheral amplification of sweating - a role for calcitonin gene-related peptide J. Physiol., November 1, 2006; 576(3): 823 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kupari, T. S. Mikkola, H. Turto, J. Lommi, and O. Ylikorkala Vasoactive intestinal peptide--release from the heart and response in heart failure due to left ventricular pressure overload Eur J Heart Fail, June 1, 2006; 8(4): 361 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hogan and F. Markos Vasoactive intestinal polypeptide receptor antagonism enhances the vagally induced increase in cardiac interval of the rat atrium in vitro Exp Physiol, May 1, 2006; 91(3): 641 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Robert, C. Norez, and F. Becq Disruption of CFTR chloride channel alters mechanical properties and cAMP-dependent Cl- transport of mouse aortic smooth muscle cells J. Physiol., October 15, 2005; 568(2): 483 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. W. Wilkins, L. H. Chung, N. J. Tublitz, B. J. Wong, and C. T. Minson Mechanisms of vasoactive intestinal peptide-mediated vasodilation in human skin J Appl Physiol, October 1, 2004; 97(4): 1291 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. POZO and M. DELGADO The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? FASEB J, September 1, 2004; 18(12): 1325 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Delgado, D. Pozo, and D. Ganea The Significance of Vasoactive Intestinal Peptide in Immunomodulation Pharmacol. Rev., June 1, 2004; 56(2): 249 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Robert, V. Thoreau, C. Norez, A. Cantereau, A. Kitzis, Y. Mettey, C. Rogier, and F. Becq Regulation of the Cystic Fibrosis Transmembrane Conductance Regulator Channel by {beta}-Adrenergic Agonists and Vasoactive Intestinal Peptide in Rat Smooth Muscle Cells and Its Role in Vasorelaxation J. Biol. Chem., May 14, 2004; 279(20): 21160 - 21168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Dilger, E. H. Rho, F. G. Que, and J. Sprung Octreotide-Induced Bradycardia and Heart Block During Surgical Resection of a Carcinoid Tumor Anesth. Analg., February 1, 2004; 98(2): 318 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. T Bennett, J. M Johnson, D. P Stephens, A. R Saad, and D. L Kellogg Jr Evidence for a Role for Vasoactive Intestinal Peptide in Active Vasodilatation in the Cutaneous Vasculature of Humans J. Physiol., October 1, 2003; 552(1): 223 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Olszewski, M. M. Wirth, T. J. Shaw, M. K. Grace, and A. S. Levine Peptides that Regulate Food Intake: Effect of peptide histidine isoleucine on consummatory behavior in rats Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2003; 284(6): R1445 - R1453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Boehm and H. Kubista Fine Tuning of Sympathetic Transmitter Release via Ionotropic and Metabotropic Presynaptic Receptors Pharmacol. Rev., March 1, 2002; 54(1): 43 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Lelievre, N. Pineau, Z. Hu, Y. Ioffe, J.-Y. Byun, J.-M. Muller, and J. A. Waschek Proliferative Actions of Natriuretic Peptides on Neuroblastoma Cells. INVOLVEMENT OF GUANYLYL CYCLASE AND NON-GUANYLYL CYCLASE PATHWAYS J. Biol. Chem., November 16, 2001; 276(47): 43668 - 43676. [Abstract] [Full Text] [PDF]
|
|